Cyclooxygenase-1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease

This study aimed at testing the hypothesis that selective COX-1 inhibition would protect the brain against AD-related neuroinflammation and improve cognitive deficits. To test this hypothesis, the authors administered the COX-1 inhibitor SC-560 to aged triple transgenic AD mice (3xTg-AD), which progressively develop extracellular amyloid plaques, intracellular neurofibrillary tangles, and cognitive impairment. Results showed that SC-560 treatment significantly reduces amyloid deposits, tau hyperphosphorylation, and neuroinflammation, and ameliorates cognitive deficits in aged 3xg-AD mice with significant pathology. These results suggest that COX-1 may play an important role in the pathogenesis of AD and a selective COX-1 inhibitor may be therapeutically beneficial in AD.